Literature DB >> 26501802

Choroidal Neovascularization Secondary to Myopia, Infection and Inflammation.

Marissa L Weber, Jeffrey S Heier.   

Abstract

Choroidal neovascularization (CNV) is a significant cause of vision loss in all age groups. The most common cause of CNV is age-related macular degeneration (AMD). However, CNV can also occur as a secondary manifestation of various inherited and acquired conditions, including pathologic myopia, presumed ocular histoplasmosis syndrome, angioid streaks, and various hereditary, traumatic or inflammatory disorders. Fluorescein angiography and optical coherence tomography are useful tools in the diagnosis and evaluation of CNV. Treatment options are similar to those for CNV secondary to AMD, specifically anti-angiogenic therapy, but including laser photocoagulation, photodynamic therapy and surgery. Anti-angiogenic therapy has been associated with better visual outcomes than other treatment modalities and is now advocated as the first-line therapy for CNV secondary to myopia, infection and inflammation.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26501802     DOI: 10.1159/000431194

Source DB:  PubMed          Journal:  Dev Ophthalmol        ISSN: 0250-3751


  11 in total

1.  Next-Generation Sequencing Screening of 43 Families with Non-Syndromic Early-Onset High Myopia: A Clinical and Genetic Study.

Authors:  Eva González-Iglesias; Ana López-Vázquez; Susana Noval; María Nieves-Moreno; María Granados-Fernández; Natalia Arruti; Irene Rosa-Pérez; Marta Pacio-Míguez; Victoria E F Montaño; Patricia Rodríguez-Solana; Angela Del Pozo; Fernando Santos-Simarro; Elena Vallespín
Journal:  Int J Mol Sci       Date:  2022-04-11       Impact factor: 6.208

2.  99Tc-MDP treatment for the therapy of rheumatoid arthritis, choroidal neovascularisation and Graves' ophthalmopathy.

Authors:  Qian Wu; Yang Ni; Qingrui Yang; Hongsheng Sun
Journal:  Biomed Rep       Date:  2016-02-23

3.  Advanced glycation end products promote VEGF expression and thus choroidal neovascularization via Cyr61-PI3K/AKT signaling pathway.

Authors:  Lijuan Sun; Tonglie Huang; Wenqin Xu; Jiaxing Sun; Yang Lv; Yusheng Wang
Journal:  Sci Rep       Date:  2017-11-02       Impact factor: 4.379

4.  Inhibition of YAP ameliorates choroidal neovascularization via inhibiting endothelial cell proliferation.

Authors:  Zhenzhen Yan; Haihong Shi; Rongrong Zhu; Lele Li; Bai Qin; Lihua Kang; Hui Chen; Huaijin Guan
Journal:  Mol Vis       Date:  2018-01-31       Impact factor: 2.367

5.  Inhibition of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor by Chrysin in a Rat Model of Choroidal Neovascularization.

Authors:  Ji Hun Song; Ka Young Moon; Sung Chul Lee; Sung Soo Kim
Journal:  Int J Mol Sci       Date:  2020-04-18       Impact factor: 5.923

6.  Long Non-Coding RNA PNKY Modulates the Development of Choroidal Neovascularization.

Authors:  Lianjun Shi; Xue Han; Chang Liu; Xiumiao Li; Shuting Lu; Qin Jiang; Jin Yao
Journal:  Front Cell Dev Biol       Date:  2022-02-21

7.  Potential role of sirtuin 1 in Müller glial cells in mice choroidal neovascularization.

Authors:  Tomoka Ishida; Takeshi Yoshida; Kosei Shinohara; Kejia Cao; Ken-Ichi Nakahama; Ikuo Morita; Kyoko Ohno-Matsui
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

8.  Comparison of choroidal neovascularization secondary to white dot syndromes and age-related macular degeneration by using optical coherence tomography angiography.

Authors:  Jay C Wang; Kenneth M McKay; Arjun B Sood; Inês Laíns; Lucia Sobrin; John B Miller
Journal:  Clin Ophthalmol       Date:  2018-12-31

Review 9.  Eph Receptors and Ephrins in Retinal Diseases.

Authors:  Radoslaw Kaczmarek; Pawel Gajdzis; Malgorzata Gajdzis
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

10.  Inflammatory Choroidal Neovascular Membranes: Clinical Profile, Treatment Effectiveness, and Visual Prognosis.

Authors:  Gonçalo Carrola; Mário Lima-Fontes; Fernando Falcão-Reis; Luís Figueira; Ângela Carneiro
Journal:  J Ophthalmol       Date:  2021-07-23       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.